Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).
Google Scholar
Sabari, B. R., Zhang, D., Allis, C. D. & Zhao, Y. Metabolic regulation of gene expression through histone acylations. Nat. Rev. Mol. Cell Biol. 18, 90–101 (2017).
Google Scholar
Badeaux, A. I. & Shi, Y. Emerging roles for chromatin as a signal integration and storage platform. Nat. Rev. Mol. Cell Biol. 14, 211–224 (2013).
Google Scholar
Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343–349 (2011).
Google Scholar
Guo, Y., Zhao, S. & Wang, G. G. Polycomb gene silencing mechanisms: PRC2 chromatin targeting, H3K27me3 ‘readout’, and phase separation-based compaction. Trends Genet. 37, 547–565 (2021).
Google Scholar
Kim, K. H. & Roberts, C. W. Targeting EZH2 in cancer. Nat. Med. 22, 128–134 (2016).
Google Scholar
Varambally, S. et al. The Polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629 (2002).
Google Scholar
Wu, S. Y. et al. The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma. BMC Immunol. 23, 28 (2022).
Google Scholar
Xu, B., Konze, K. D., Jin, J. & Wang, G. G. Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp. Hematol. 43, 698–712 (2015).
Google Scholar
Kang, Y., Zhang, Y. & Sun, Y. Comprehensive analysis of the expression characteristics of the enhancer of the zeste homolog 2 gene in pan-cancer. Front. Genet. 12, 658241 (2021).
Google Scholar
Xu, K. et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338, 1465–1469 (2012).
Google Scholar
Venkadakrishnan, V. B. et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat. Commun. 15, 6779 (2024).
Google Scholar
Chatterjee, S. S. et al. Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer. Nat. Commun. 15, 9755 (2024).
Google Scholar
Lee, S. T. et al. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol. Cell 43, 798–810 (2011).
Google Scholar
Wei, Y. et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat. Cell Biol. 13, 87–94 (2011).
Google Scholar
Yan, J. et al. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. Blood 128, 948–958 (2016).
Google Scholar
Wang, J. et al. EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Nat. Cell Biol. 24, 384–399 (2022).
Google Scholar
Wang, L. et al. EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation. Nat. Commun. 13, 12 (2022).
Google Scholar
Brown, M. S. & Goldstein, J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331–340 (1997).
Google Scholar
Mullen, P. J., Yu, R., Longo, J., Archer, M. C. & Penn, L. Z. The interplay between cell signalling and the mevalonate pathway in cancer. Nat. Rev. Cancer 16, 718–731 (2016).
Google Scholar
Yap, D. B. et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451–2459 (2011).
Google Scholar
Dale, B. et al. Advancing targeted protein degradation for cancer therapy. Nat. Rev. Cancer 21, 638–654 (2021).
Google Scholar
Rumgay, H. et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 77, 1598–1606 (2022).
Google Scholar
Arzumanian, V. A., Kiseleva, O. I. & Poverennaya, E. V. The curious case of the HepG2 cell line: 40 years of expertise. Int. J. Mol. Sci. 22, 13135 (2021).
Google Scholar
Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125–1131 (2002).
Google Scholar
Seo, Y. K. et al. Genome-wide localization of SREBP-2 in hepatic chromatin predicts a role in autophagy. Cell Metab. 13, 367–375 (2011).
Google Scholar
Valenza, M., Birolini, G. & Cattaneo, E. The translational potential of cholesterol-based therapies for neurological disease. Nat. Rev. Neurol. 19, 583–598 (2023).
Google Scholar
Duan, Y. et al. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct. Target Ther. 7, 265 (2022).
Google Scholar
Huang, B., Song, B. L. & Xu, C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat. Metab. 2, 132–141 (2020).
Google Scholar
Juarez, D. & Fruman, D. A. Targeting the mevalonate pathway in cancer. Trends Cancer 7, 525–540 (2021).
Google Scholar
Schug, Z. T. et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 27, 57–71 (2015).
Google Scholar
Mesmin, B. et al. STARD4 abundance regulates sterol transport and sensing. Mol. Biol. Cell 22, 4004–4015 (2011).
Google Scholar
Paton, C. M. & Ntambi, J. M. Biochemical and physiological function of stearoyl-CoA desaturase. Am. J. Physiol. Endocrinol. Metab. 297, E28–E37 (2009).
Google Scholar
Hu, A. et al. PIP4K2A regulates intracellular cholesterol transport through modulating PI(4,5)P(2) homeostasis. J. Lipid Res. 59, 507–514 (2018).
Google Scholar
Wang, S. et al. Target analysis by integration of transcriptome and ChIP-seq data with BETA. Nat. Protoc. 8, 2502–2515 (2013).
Google Scholar
Jiao, L. et al. A partially disordered region connects gene repression and activation functions of EZH2. PNAS 117, 16992–17002 (2020).
Google Scholar
Becht, D. C. et al. Multiple transactivation domains of EZH2 bind to the TAZ2 domain of p300 and stimulate the acetyltransferase function of p300. Biochem. J. 482, 955–968 (2025).
Google Scholar
Giandomenico, V., Simonsson, M., Gronroos, E. & Ericsson, J. Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol. Cell. Biol. 23, 2587–2599 (2003).
Google Scholar
Janicki, S. M. et al. From silencing to gene expression: real-time analysis in single cells. Cell 116, 683–698 (2004).
Google Scholar
Chong, S. et al. Imaging dynamic and selective low-complexity domain interactions that control gene transcription. Science 361, eaar2555 (2018).
Google Scholar
Lyons, H. et al. Functional partitioning of transcriptional regulators by patterned charge blocks. Cell 186, 327–345 e328 (2023).
Google Scholar
Cardinaux, J. R. et al. Recruitment of CREB binding protein is sufficient for CREB-mediated gene activation. Mol. Cell. Biol. 20, 1546–1552 (2000).
Google Scholar
Chen, Z. et al. Discovery of CBPD-268 as an exceptionally potent and orally efficacious CBP/p300 PROTAC degrader capable of achieving tumor regression. J. Med. Chem. 67, 5275–5304 (2024).
Google Scholar
Knutson, S. K. et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl Acad. Sci. USA 110, 7922–7927 (2013).
Google Scholar
Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732–736 (2009).
Google Scholar
Webb, T., Craigon, C. & Ciulli, A. Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective. Bioorg. Med. Chem. Lett. 63, 128653 (2022).
Google Scholar
Dale, B. et al. Targeting triple-negative breast cancer by a novel proteolysis targeting chimera degrader of enhancer of zeste homolog 2. ACS Pharmacol. Transl. Sci. 5, 491–507 (2022).
Google Scholar
Sato, R. et al. Sterol-dependent transcriptional regulation of sterol regulatory element-binding protein-2. J. Biol. Chem. 271, 26461–26464 (1996).
Google Scholar
Hsu, J. H. et al. EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex. Cell Chem. Biol. 27, 41–46 e17 (2020).
Google Scholar
Chen, H. A. et al. Senescence rewires microenvironment sensing to facilitate antitumor immunity. Cancer Discov. 13, 432–453 (2023).
Google Scholar
Mok, E. H. K. et al. Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma. Cancer Res. 82, 3102–3115 (2022).
Google Scholar
Gao, S. et al. CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer. Oncogene 40, 6601–6613 (2021).
Google Scholar
Kong, Y. et al. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC). J. Biol. Chem. 293, 14328–14341 (2018).
Google Scholar
Shimada, K. et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol. 12, 497–503 (2016).
Google Scholar
Li, W., Liang, L., Liu, S., Yi, H. & Zhou, Y. FSP1: a key regulator of ferroptosis. Trends Mol. Med. 29, 753–764 (2023).
Google Scholar
Sun, H. et al. p53 transcriptionally regulates SQLE to repress cholesterol synthesis and tumor growth. EMBO Rep. 22, e52537 (2021).
Google Scholar
Muta, Y. et al. Enhanced SREBP2-driven cholesterol biosynthesis by PKClambda/iota deficiency in intestinal epithelial cells promotes aggressive serrated tumorigenesis. Nat. Commun. 14, 8075 (2023).
Google Scholar
Zhang, T., Gong, Y., Meng, H., Li, C. & Xue, L. Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor. Clin. Epigenetics 12, 72 (2020).
Google Scholar
Niccolai, R. et al. Cholesterol biosynthesis as a drug-induced vulnerability in diffuse large B cell lymphoma insensitive to EZH2 inhibition. Neoplasia 70, 101243 (2025).
Google Scholar
Yang, P. M., Hong, Y. H., Hsu, K. C. & Liu, T. P. p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma. Am. J. Cancer Res. 9, 2120–2139 (2019).
Google Scholar
Kamisuki, S. et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem. Biol. 16, 882–892 (2009).
Google Scholar
Zheng, L., Li, L., Lu, Y., Jiang, F. & Yang, X. A. SREBP2 contributes to cisplatin resistance in ovarian cancer cells. Exp. Biol. Med. 243, 655–662 (2018).
Google Scholar
Cha, T. L. et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310, 306–310 (2005).
Google Scholar
Hao, A., Wang, Y., Stovall, D. B., Wang, Y. & Sui, G. Emerging roles of LncRNAs in the EZH2-regulated oncogenic network. Int. J. Biol. Sci. 17, 3268–3280 (2021).
Google Scholar
Wang, J. & Wang, G. G. No easy way out for EZH2: its pleiotropic, noncanonical effects on gene regulation and cellular function. Int. J. Mol. Sci. 21, E9501 (2020).
Google Scholar
Yi, Y. et al. A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR. Nat. Commun. https://doi.org/10.1038/s41467-026-71207-3 (2026).
Song, J. et al. Structural basis for inactivation of PRC2 by G-quadruplex RNA. Science 381, 1331–1337 (2023).
Google Scholar
Kim, E. et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23, 839–852 (2013).
Google Scholar
Park, K. S. et al. Targeted degradation of PRC1 components, BMI1 and RING1B, via a novel protein complex degrader strategy. Adv. Sci. 10, e2205573 (2023).
Google Scholar
Xiong, Y. et al. Bridged proteolysis targeting chimera (PROTAC) enables degradation of undruggable targets. J. Am. Chem. Soc. 144, 22622–22632 (2022).
Google Scholar
Ahn, J. H. et al. The phenylalanine-and-glycine repeats of NUP98 oncofusions form condensates that selectively partition transcriptional coactivators. Mol. Cell 85, 708–725 e709 (2025).
Google Scholar
Yang, X. et al. Structure-activity relationship studies for enhancer of zeste homologue 2 (EZH2) and enhancer of zeste homologue 1 (EZH1) inhibitors. J. Med. Chem. 59, 7617–7633 (2016).
Google Scholar
Knutson, S. K. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890–896 (2012).
Google Scholar
Yu, X. et al. A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models. Sci. Transl. Med. 13, eabj1578 (2021).
Google Scholar
Cai, L. et al. ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in castrate-resistant prostate cancer. Mol. Cell 72, 341–354 e346 (2018).
Google Scholar
Meers, M. P., Bryson, T. D., Henikoff, J. G. & Henikoff, S. Improved CUT&RUN chromatin profiling tools. Elife 8, e46314 (2019).
Google Scholar
Zhao, S. et al. TNRC18 engages H3K9me3 to mediate silencing of endogenous retrotransposons. Nature 623, 633–642 (2023).
Google Scholar
Kaya-Okur, H. S. et al. CUT&Tag for efficient epigenomic profiling of small samples and single cells. Nat. Commun. 10, 1930 (2019).
Google Scholar
Yu, Y. et al. Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma. Sci. Adv. 11, eads7876 (2025).
Google Scholar
Li, D. et al. BAHCC1 binds H4K20me1 to facilitate the MCM complex loading and DNA replication. Nat. Commun. 16, 5502 (2025).
Google Scholar
Zhu, L. J. et al. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinform. 11, 237 (2010).
Google Scholar
Ortega, E. et al. Transcription factor dimerization activates the p300 acetyltransferase. Nature 562, 538–544 (2018).
Google Scholar
Zeng, X., Herndon, A. M. & Hu, J. C. Buried asparagines determine the dimerization specificities of leucine zipper mutants. Proc. Natl Acad. Sci. USA 94, 3673–3678 (1997).
Google Scholar
Scheer, S. et al. A chemical biology toolbox to study protein methyltransferases and epigenetic signaling. Nat. Commun. 10, 19 (2019).
Google Scholar
